* Recruitment 70% complete for only vaccine in Phase III targeting pancreatic
cancer
* Breakthrough potential as “universal” therapeutic cancer vaccine
OSLO, Norway–(Business Wire)–
KAEL-GemVax, a leading oncology vaccine company, today announced, through its
subsidiary GemVax A.S, encouraging interim progress from the UK-based Phase III
TeloVac study of its anti-telomerase therapeutic cancer vaccine GV1001 in
pancreatic cancer. The company also strongly believes GV1001 has major
“blockbuster” potential as a universal therapeutic cancer vaccine and is
developing a strong pipeline for other indications, including lung and liver
cancer and melanoma.
The largest cancer vaccine therapy trial ever in the UK, currently funded by
Cancer Research UK, the TeloVac study is being run by the Liverpool Cancer
Trials Unit. KAEL-GemVax has just received the second interim report noting that
the number of patients recruited reached 755 out of 1110 in 52 centres in the UK
in June. This means recruitment is now almost 70% complete and remains well on
schedule for LPFV in October 2011 and NDA filing soon after. A recent
Datamonitor report forecasted the market for therapeutic cancer vaccines to
reach $4.7 billion by 2018 in 7 major markets.
Director of the LCTU, Professor John Neoptolemos commented: “GV1001 is the most
advanced therapeutic cancer vaccine currently in development and we are
extremely pleased with the progress of trials so far. Patient recruitment across
our centres continues and we are seeing some good immunological responses.”
The primary trial objective is length of survival. The TeloVac study was
initiated in 2007 after the Phase I/II study showed overall survival of 8.6
months, compared to the 5.6 months of current standard treatment Gemcitabine. It
is a prospective, controlled, multicentre, randomised clinical trial comparing
combination Gemcitabine and Capecitabine therapy with concurrent and sequential
chemoimmunotherapy using a telomerase vaccine in locally advanced and metastatic
pancreatic cancer.
KAEL-GemVax CEO Dr Jay Sangjae Kim added: “These results from the independent
Data Monitoring Committee on the TeloVac trial in the UK are extremely
encouraging. Currently pancreatic cancer is one of the most difficult cancers to
treat and there are only a few approved treatments on the market. However, we
believe that the improved overall survival and favourable safety profile that
GVI001 has shown in previous studies creates a strong rationale for providing it
with standard care, and thus creating the first therapeutic vaccine for patients
with pancreatic cancer. In addition, we strongly believe that GV1001 has the
potential to overcome the limits of other current cancer vaccines and become
part of the standard of care not only for pancreatic cancer but for various
other types of cancers. In other words a truly “universal” vaccine will be
available in the near future.”
Corporate Inquiries
KAEL-GemVax
Yena Chung, Global PR Manager
Tel: +82-2 540 6221
Email: yenachung@kaelgemvax.com
or
Media Inquiries
Schwartz Communications
Richard Hayhurst
Tel: +44 (0)7950 878 218
Email: Rhayhurst@schwatrtzcomm.com
or
Schwartz Communications US
Ben Navon
Tel: +1 781-684-0770
Email: Bnavon@schwartzcomm.com
Copyright Business Wire 2010
